BAM
RVMD icon

Belpointe Asset Management’s Revolution Medicines RVMD Stock Holding History

Belpointe Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,078
Closed -$25.7K – 3834
2022
Q4 		$25.7K Buy
+1,078
New +$22.9K ﹤0.01% 2005

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Belpointe Asset Management's RVMD Position: Q1 2023 in Review

Belpointe Asset Management sold out of Revolution Medicines (RVMD) in Q1 2023, closing a stake of 1,078 shares — an estimated $25.7K sold.

Belpointe Asset Management first reported a position in RVMD in Q4 2022 and held it in 1 quarter. The position peaked at $25.7K in Q4 2022. 152 funds tracked by Wall St. Rank hold RVMD as of Q1 2023.

  • Belpointe Asset Management reported no remaining Revolution Medicines position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,078 Revolution Medicines shares in Q1 2023, an estimated $25.7K.
  • Belpointe Asset Management first reported a position in Revolution Medicines in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Revolution Medicines position peaked at $25.7K in Q4 2022.
  • 152 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.